Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Junctional adhesion molecule-A (JAM-A), also known as F11 receptor (F11R), is a transmembrane glycoprotein that is involved in various biological processes, including cancer initiation and progression. However, the functional characteristics and significance of JAM-A in pan-cancer remain unexplored. In this study, we used multiple databases to gain a comprehensive understanding of JAM-A in human cancers. JAM-A was widely expressed in various tissues, mainly located on the microtubules and cell junctions. Aberrant expression of JAM-A was detected in multiple cancers at both mRNA and protein levels, which can be correlated with poorer prognosis and may be attributed to genetic alterations and down-regulated DNA methylation. JAM-A expression was also associated with immune infiltration and may affect immunotherapy responses in several cancers. Functional enrichment analysis indicated that JAM-A participated in tight junction and cancer-related pathways. In vitro experiments verified that JAM-A knockdown suppressed the proliferation and migration abilities of breast cancer cells and liver cancer cells. Overall, our study suggests that JAM-A is a pan-cancer regulator and a potential biomarker for predicting prognosis and immune-therapeutic responses for different tumors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11275048PMC
http://dx.doi.org/10.3390/biomedicines12071423DOI Listing

Publication Analysis

Top Keywords

jam-a
10
jam-a pan-cancer
8
cancer cells
8
identification validation
4
validation jam-a
4
jam-a novel
4
novel prognostic
4
prognostic immune
4
immune factor
4
factor human
4

Similar Publications

: CNCM I-745, a probiotic yeast, is effectively used for the treatment of acute diarrhea as well as for the prevention and treatment of traveller's diarrhea and diarrhea under tube feeding. The underlying mechanisms are not fully elucidated. Both antitoxic and regulatory effects on the intestinal barrier, mediated either by the yeast or yeast-derived substrates, have been discussed.

View Article and Find Full Text PDF

Health and research systems produce vast amounts of data, yet only a fraction is used to improve healthcare delivery-especially for equity-deserving communities. In Canada, Learning Health Systems (LHS) are guided by the Quadruple Aim: improving population health, enhancing patient and provider experience, and reducing costs, with equity now recognized as a critical additional aim. As LHS evolve, advancing health equity has become a core driver, particularly in Canada.

View Article and Find Full Text PDF

This study investigated the precise alleviating mechanisms of Zn on chick embryonic jejunal epithelial cells under thermal stress (TS) and elucidated signaling pathways directly involved in this process. Experiment 1 identified the effective concentrations of inhibitors or agonists for extracellular regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT). The data were analyzed using one-way ANOVA.

View Article and Find Full Text PDF

JAM-A: Adhesion Receptor and Signaling Regulator in Atherosclerosis.

Curr Atheroscler Rep

July 2025

Institute-associated Research Group "Cell adhesion and cell polarity", Institute of Medical Biochemistry, ZMBE, University of Münster, 48419, Münster, Germany.

Purpose Of Review: Cell-cell adhesion between leukocytes, platelets and endothelial cells plays a critical role in vascular inflammation and thrombus formation. This review aims at providing a comprehensive picture of the contribution of the immunoglobulin superfamily (IgSF) cell adhesion receptor Junctional Adhesion Molecule-A (JAM-A) to the process of atherosclerosis.

Recent Findings: Proinflammatory and proatherogenic stimulation of endothelial cells results in redistribution of JAM-A from cell-cell junctions to the apical surface to promote monocyte adhesion and transmigration.

View Article and Find Full Text PDF

Lactate Is a Major Promotor of Breast Cancer Cell Aggressiveness.

Cancers (Basel)

May 2025

Department of Pharmaceutical Chemistry, College of Pharmacy, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait.

: Lactate dehydrogenase (LDH) activity, producing high levels of lactate from pyruvate in cancer cells, is often associated with poor patient prognosis. We previously showed enhanced LDH/lactate levels in estrogen receptor (ER) compared to ER + breast cancer cells; lactate or pyruvate supplementation to ER + cells significantly enhanced their motile ability, while LDHB gene knockout (KO) or treatment with LDH inhibitors reduced the motility of the highly aggressive ER breast cancer cells. : To investigate the molecular mechanisms by which lactate, LDHB KO, or treatment with LDH inhibitors can modulate the motile capabilities of breast cancer cell lines.

View Article and Find Full Text PDF